Cargando…

Research Note: Effects of Escherichia coli co-infection on the protective efficacy assessment of two common infectious bronchitis vaccines

Avian infectious bronchitis (IB), a highly contagious disease hazardous to the poultry industry, is caused by an etiological agent called the infectious bronchitis virus (IBV). Some IBV strains (IBVs) alone usually do not cause high mortality in field conditions if not with secondary pathogens inclu...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Yu-Xi, Li, Wen-Wen, Xia, Jing, Du, Ji-Teng, Li, Shu-Yun, Chen, Wen, Cui, Min, Han, Xin-Feng, Huang, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350523/
https://www.ncbi.nlm.nih.gov/pubmed/34358949
http://dx.doi.org/10.1016/j.psj.2021.101324
_version_ 1783735781080170496
author Shen, Yu-Xi
Li, Wen-Wen
Xia, Jing
Du, Ji-Teng
Li, Shu-Yun
Chen, Wen
Cui, Min
Han, Xin-Feng
Huang, Yong
author_facet Shen, Yu-Xi
Li, Wen-Wen
Xia, Jing
Du, Ji-Teng
Li, Shu-Yun
Chen, Wen
Cui, Min
Han, Xin-Feng
Huang, Yong
author_sort Shen, Yu-Xi
collection PubMed
description Avian infectious bronchitis (IB), a highly contagious disease hazardous to the poultry industry, is caused by an etiological agent called the infectious bronchitis virus (IBV). Some IBV strains (IBVs) alone usually do not cause high mortality in field conditions if not with secondary pathogens including Escherichia coli (E. coli). Herein, we established an IBV and E. coli co-infection model to evaluate the protective efficacy of two IBV vaccine strains against a new emerging genotype GVI-1 with mild virulence in experimental conditions. Chickens were inoculated with IBV field isolate ZQX (genotype GVI-1) and challenged 4 dlater with the E. coli strain MS160427 (serotype O8). Subsequently, these chickens were euthanized at seven days postchallenge (d.p.c.) with E. coli. An autopsy revealed that lesions in the IBV plus E. coli co-infection group were more severe than those in the IBV-infected group. This pathological model was used to assess the protective effect of two commonly used vaccine strains (H120 and 4/91) against the IBV ZQX strain, and a significantly better protective efficacy was observed for 4/91 compared with H120. Thus, IBV and E. coli co-infection could be employed in assessing the protective efficacy of IBV vaccines.
format Online
Article
Text
id pubmed-8350523
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-83505232021-08-15 Research Note: Effects of Escherichia coli co-infection on the protective efficacy assessment of two common infectious bronchitis vaccines Shen, Yu-Xi Li, Wen-Wen Xia, Jing Du, Ji-Teng Li, Shu-Yun Chen, Wen Cui, Min Han, Xin-Feng Huang, Yong Poult Sci IMMUNOLOGY, HEALTH AND DISEASE Avian infectious bronchitis (IB), a highly contagious disease hazardous to the poultry industry, is caused by an etiological agent called the infectious bronchitis virus (IBV). Some IBV strains (IBVs) alone usually do not cause high mortality in field conditions if not with secondary pathogens including Escherichia coli (E. coli). Herein, we established an IBV and E. coli co-infection model to evaluate the protective efficacy of two IBV vaccine strains against a new emerging genotype GVI-1 with mild virulence in experimental conditions. Chickens were inoculated with IBV field isolate ZQX (genotype GVI-1) and challenged 4 dlater with the E. coli strain MS160427 (serotype O8). Subsequently, these chickens were euthanized at seven days postchallenge (d.p.c.) with E. coli. An autopsy revealed that lesions in the IBV plus E. coli co-infection group were more severe than those in the IBV-infected group. This pathological model was used to assess the protective effect of two commonly used vaccine strains (H120 and 4/91) against the IBV ZQX strain, and a significantly better protective efficacy was observed for 4/91 compared with H120. Thus, IBV and E. coli co-infection could be employed in assessing the protective efficacy of IBV vaccines. Elsevier 2021-06-17 /pmc/articles/PMC8350523/ /pubmed/34358949 http://dx.doi.org/10.1016/j.psj.2021.101324 Text en © 2021 Published by Elsevier Inc. on behalf of Poultry Science Association Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle IMMUNOLOGY, HEALTH AND DISEASE
Shen, Yu-Xi
Li, Wen-Wen
Xia, Jing
Du, Ji-Teng
Li, Shu-Yun
Chen, Wen
Cui, Min
Han, Xin-Feng
Huang, Yong
Research Note: Effects of Escherichia coli co-infection on the protective efficacy assessment of two common infectious bronchitis vaccines
title Research Note: Effects of Escherichia coli co-infection on the protective efficacy assessment of two common infectious bronchitis vaccines
title_full Research Note: Effects of Escherichia coli co-infection on the protective efficacy assessment of two common infectious bronchitis vaccines
title_fullStr Research Note: Effects of Escherichia coli co-infection on the protective efficacy assessment of two common infectious bronchitis vaccines
title_full_unstemmed Research Note: Effects of Escherichia coli co-infection on the protective efficacy assessment of two common infectious bronchitis vaccines
title_short Research Note: Effects of Escherichia coli co-infection on the protective efficacy assessment of two common infectious bronchitis vaccines
title_sort research note: effects of escherichia coli co-infection on the protective efficacy assessment of two common infectious bronchitis vaccines
topic IMMUNOLOGY, HEALTH AND DISEASE
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350523/
https://www.ncbi.nlm.nih.gov/pubmed/34358949
http://dx.doi.org/10.1016/j.psj.2021.101324
work_keys_str_mv AT shenyuxi researchnoteeffectsofescherichiacolicoinfectionontheprotectiveefficacyassessmentoftwocommoninfectiousbronchitisvaccines
AT liwenwen researchnoteeffectsofescherichiacolicoinfectionontheprotectiveefficacyassessmentoftwocommoninfectiousbronchitisvaccines
AT xiajing researchnoteeffectsofescherichiacolicoinfectionontheprotectiveefficacyassessmentoftwocommoninfectiousbronchitisvaccines
AT dujiteng researchnoteeffectsofescherichiacolicoinfectionontheprotectiveefficacyassessmentoftwocommoninfectiousbronchitisvaccines
AT lishuyun researchnoteeffectsofescherichiacolicoinfectionontheprotectiveefficacyassessmentoftwocommoninfectiousbronchitisvaccines
AT chenwen researchnoteeffectsofescherichiacolicoinfectionontheprotectiveefficacyassessmentoftwocommoninfectiousbronchitisvaccines
AT cuimin researchnoteeffectsofescherichiacolicoinfectionontheprotectiveefficacyassessmentoftwocommoninfectiousbronchitisvaccines
AT hanxinfeng researchnoteeffectsofescherichiacolicoinfectionontheprotectiveefficacyassessmentoftwocommoninfectiousbronchitisvaccines
AT huangyong researchnoteeffectsofescherichiacolicoinfectionontheprotectiveefficacyassessmentoftwocommoninfectiousbronchitisvaccines